An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Lung Adenocarcinoma

Qian Xu, Yurong ChenFrontiers in Cell and Developmental Biology 2021 · DOI

TL;DR

This study introduces a novel six-gene "aging signature" that accurately predicts the prognosis of lung adenocarcinoma (LUAD) patients. This signature, built from aging-related genes (ARGs), offers a more precise risk stratification tool than traditional staging systems and has been integrated into a user-friendly web calculator for clinical application.

What Problem Does This Paper Address?

Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality worldwide, characterized by high heterogeneity and a lack of effective prognostic biomarkers. While aging is a known risk factor for many diseases, including cancer, its specific role in LUAD prognosis and the development of targeted therapeutic strategies has been unclear. Existing prognostic models often fall short, necessitating the exploration of new molecular markers. This paper aims to address this gap by investigating the potential of aging-related genes (ARGs) as prognostic indicators for LUAD and developing a robust predictive model.

Methods

The researchers employed a multi-step bioinformatics approach to identify and validate the ARG signature. They began by analyzing ARG expression data from large public datasets (TCGA and GEO).

  • Univariate Cox Regression: This initial screening identified ARGs significantly associated with overall survival (OS).
  • LASSO Regression: To reduce the number of candidate genes and prevent overfitting, the Least Absolute Shrinkage and Selection Operator (LASSO) regression was applied. This method effectively shrinks the coefficients of less important genes to zero, selecting a parsimonious set of predictors.
  • Multivariate Cox Regression: This final step was used to build the prognostic signature by identifying independent predictors among the selected ARGs.
  • Risk Score Calculation: A risk score was computed for each patient based on a linear combination of the expression levels of the identified ARGs, weighted by their regression coefficients.
  • Nomogram Development: To integrate the ARG signature with clinical factors (age, sex, stage), a nomogram was constructed. This graphical tool allows for the calculation of an individual patient's probability of survival at specific time points.
  • Validation: The signature and nomogram were validated in an independent dataset (GEO cohort) to ensure their generalizability.
  • Web-based Calculator: A user-friendly web application was developed to facilitate the practical application of the nomogram.
  • Gene Set Enrichment Analysis (GSEA): GSEA was used to explore the potential biological pathways and mechanisms associated with the identified ARG signature.
  • Immune Infiltration Analysis: The ESTIMATE algorithm was used to assess the relationship between the ARG signature and immune cell infiltration in the tumor microenvironment.

Datasets

  • The Cancer Genome Atlas (TCGA): Used as the primary training dataset for developing the ARG signature and nomogram.
  • Gene Expression Omnibus (GEO) dataset (specifically GSE31210): Used as an independent validation dataset to confirm the performance of the developed signature and nomogram.

Key Insights and Ideas

  • Aging as a Prognostic Factor in LUAD: The study strongly suggests that aging processes, as reflected by specific ARGs, play a significant role in the prognosis of LUAD, going beyond traditional clinical indicators.
  • A Robust Six-Gene Signature: The identification of a specific set of six ARGs (APOC3, EPOR, H2AFX, MXD1, PLCG2, and YWHAZ) that consistently predict survival outcomes is a major breakthrough. This signature is more than just a collection of genes; it represents a unified biological process influencing LUAD progression.
  • Nomogram Superiority: The developed nomogram, incorporating both the ARG signature and clinical factors, demonstrates superior predictive accuracy and clinical utility compared to conventional staging systems, offering a more nuanced assessment of patient risk.
  • Translational Potential: The creation of a web-based calculator makes this advanced prognostic tool accessible to clinicians, bridging the gap between research findings and clinical practice.

Key Results

  • Six-Gene Signature Identified: A signature comprising APOC3, EPOR, H2AFX, MXD1, PLCG2, and YWHAZ was constructed and found to significantly stratify LUAD patients into high- and low-risk groups for overall survival (OS).
  • Independent Prognostic Factor: The ARG signature was identified as an independent prognostic factor for LUAD, even after adjusting for clinicopathological features.
  • Nomogram Performance: The nomogram demonstrated good calibration and discrimination. In the training set, AUC values for 1-, 3-, and 5-year OS were 0.754, 0.73, and 0.742, respectively. In the validation set, these values were 0.923, 0.803, and 0.752 for OS, and comparable for relapse-free survival (RFS).
  • Clinical Utility: Decision curve analysis (DCA) indicated that the nomogram model provided a higher net benefit than the TNM staging system, suggesting its greater clinical usefulness.
  • Immune Microenvironment Link: The study found correlations between the ARG signature and immune cell infiltration, suggesting that aging-related genes may influence the tumor immune microenvironment, which could have implications for immunotherapy.

Limitations and Future Work

  • Independent Cohort Validation: The authors acknowledge that further validation in more independent LUAD cohorts is necessary to solidify the findings.
  • Experimental Validation: The study relied on bioinformatics analysis. Experimental validation of the identified ARGs' mechanisms and prognostic significance is crucial.
  • Underlying Mechanisms: While GSEA provided insights into enriched pathways (e.g., oocyte meiosis, cell cycle, basal transcription factors), further research is needed to fully elucidate the precise biological mechanisms by which these ARGs influence LUAD progression and prognosis.
  • Immune Cell Role: The specific roles of the differentially infiltrated immune cells in the context of the ARG signature and LUAD prognosis require further investigation.

Summary updated

Abstract

Aging is an inevitable time-dependent process associated with a gradual decline in many physiological functions. Importantly, some studies have supported that aging may be involved in the development of lung adenocarcinoma (LUAD). However, no studies have described an aging-related gene (ARG)-based prognosis signature for LUAD. Accordingly, in this study, we analyzed ARG expression data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). After LASSO and Cox regression analyses, a six ARG-based signature (<i>APOC3</i>, <i>EPOR</i>, <i>H2AFX</i>, <i>MXD1</i>, <i>PLCG2</i>, and <i>YWHAZ</i>) was constructed using TCGA dataset that significantly stratified cases into high- and low-risk groups in terms of overall survival (OS). Cox regression analysis indicated that the ARG signature was an independent prognostic factor in LUAD. A nomogram based on the ARG signature and clinicopathological factors was developed in TCGA cohort and validated in the GEO dataset. Moreover, to visualize the prediction results, we established a web-based calculator yurong.shinyapps.io/ARGs_LUAD/. Calibration plots showed good consistency between the prediction of the nomogram and actual observations. Receiver operating characteristic curve and decision curve analyses indicated that the ARG nomogram had better OS prediction and clinical net benefit than the staging system. Taken together, these results established a genetic signature for LUAD based on ARGs, which may promote individualized treatment and provide promising novel molecular markers for immunotherapy.
BibTeX
@inproceedings{xu2021aging,
  author = {Qian Xu and Yurong Chen},
  title = {{An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Lung Adenocarcinoma}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2021},
  doi = {10.3389/fcell.2021.685379},
}
Figure